NCI-designated cancer centers will soon be able to extend their Cancer Center Support Grant award period from five years to seven years, depending on merit at peer review, sustained exceptional progress, stability, and longevity of the cancer center.
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.
